CureVac Launches Specialized Phase 3 Clinical Trial of Coronavirus Vaccine Candidate
A coronavirus vaccine candidate similar to that of recently approved ones from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) has now moved into late-stage testing on healthcare workers.
CureVac (NASDAQ: CVAC), like BioNTech a clinical-stage biotech based in Europe, announced Monday that its CvnCoV is about to enter phase 3 clinical trials, in testing that involves healthcare workers. The first participant in the study is to be administered the initial shot of the vaccine candidate on Tuesday.
Image source: Getty Images.
Source Fool.com
